Literature DB >> 20538762

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

Hee Dong Han1, Lingegowda S Mangala, Jeong Won Lee, Mian M K Shahzad, Hye Sun Kim, Deyu Shen, Eun Ji Nam, Edna M Mora, Rebecca L Stone, Chunhua Lu, Sun Joo Lee, Ju Won Roh, Alpa M Nick, Gabriel Lopez-Berestein, Anil K Sood.   

Abstract

PURPOSE: This study aimed to develop an Arg-Gly-Asp (RGD) peptide-labeled chitosan nanoparticle (RGD-CH-NP) as a novel tumor targeted delivery system for short interfering RNA (siRNA). EXPERIMENTAL
DESIGN: RGD peptide conjugated with chitosan by thiolation reaction was confirmed by proton-NMR (H-NMR). Binding of RGD-CH-NP with alphanubeta3 integrin was examined by flow cytometry and fluorescence microscopy. Antitumor efficacy was examined in orthotopic mouse models of ovarian carcinoma.
RESULTS: We show that RGD-CH-NP loaded with siRNA significantly increased selective intratumoral delivery in orthotopic animal models of ovarian cancer. In addition, we show targeted silencing of multiple growth-promoting genes (POSTN, FAK, and PLXDC1) along with therapeutic efficacy in the SKOV3ip1, HeyA8, and A2780 models using siRNA incorporated into RGD-CH-NP (siRNA/RGD-CH-NP). Furthermore, we show in vivo tumor vascular targeting using RGD-CH-NP by delivering PLXDC1-targeted siRNA into the alphanubeta3 integrin-positive tumor endothelial cells in the A2780 tumor-bearing mice. This approach resulted in significant inhibition of tumor growth compared with controls.
CONCLUSIONS: This study shows that RGD-CH-NP is a novel and highly selective delivery system for siRNA with the potential for broad applications in human disease. (c) 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538762      PMCID: PMC2912984          DOI: 10.1158/1078-0432.CCR-10-0005

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing.

Authors:  Xiudong Liu; Kenneth A Howard; Mingdong Dong; Morten Ø Andersen; Ulrik L Rahbek; Mads G Johnsen; Ole C Hansen; Flemming Besenbacher; Jørgen Kjems
Journal:  Biomaterials       Date:  2007-02       Impact factor: 12.479

Review 2.  RNAi therapeutics: principles, prospects and challenges.

Authors:  Lars Aagaard; John J Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

Review 3.  Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.

Authors:  Saghir Akhtar; Ibrahim Benter
Journal:  Adv Drug Deliv Rev       Date:  2007-03-21       Impact factor: 15.470

4.  Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting.

Authors:  Amitava Mitra; Tomika Coleman; Mark Borgman; Anjan Nan; Hamidreza Ghandehari; Bruce R Line
Journal:  J Control Release       Date:  2006-06-17       Impact factor: 9.776

5.  Development and characterisation of chitosan nanoparticles for siRNA delivery.

Authors:  Haliza Katas; H Oya Alpar
Journal:  J Control Release       Date:  2006-07-25       Impact factor: 9.776

6.  Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.

Authors:  Chunhua Lu; Tomas Bonome; Yang Li; Aparna A Kamat; Liz Y Han; Rosemarie Schmandt; Robert L Coleman; David M Gershenson; Robert B Jaffe; Michael J Birrer; Anil K Sood
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

7.  Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner.

Authors:  Chunfu Zhang; Manfred Jugold; Eva C Woenne; Twan Lammers; Bernd Morgenstern; Margareta M Mueller; Hanswalter Zentgraf; Michael Bock; Michael Eisenhut; Wolfhard Semmler; Fabian Kiessling
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

8.  Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.

Authors:  Derek W Bartlett; Mark E Davis
Journal:  Bioconjug Chem       Date:  2007-02-28       Impact factor: 4.774

9.  Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity.

Authors:  Andrew J Hollins; Yadollah Omidi; Ibrahim F Benter; Saghir Akhtar
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

Review 10.  Periostin: novel diagnostic and therapeutic target for cancer.

Authors:  Y Kudo; B S M S Siriwardena; H Hatano; I Ogawa; T Takata
Journal:  Histol Histopathol       Date:  2007-10       Impact factor: 2.303

View more
  63 in total

1.  In vivo sustained release of siRNA from solid lipid nanoparticles.

Authors:  Tatsiana Lobovkina; Gunilla B Jacobson; Emilio Gonzalez-Gonzalez; Robyn P Hickerson; Devin Leake; Roger L Kaspar; Christopher H Contag; Richard N Zare
Journal:  ACS Nano       Date:  2011-11-18       Impact factor: 15.881

Review 2.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

Review 3.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

Review 4.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

Review 5.  RNA interference and cancer therapy.

Authors:  Zhaohui Wang; Donald D Rao; Neil Senzer; John Nemunaitis
Journal:  Pharm Res       Date:  2011-10-19       Impact factor: 4.200

Review 6.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

7.  Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.

Authors:  Adam D Steg; Ashwini A Katre; Blake Goodman; Hee-Dong Han; Alpa M Nick; Rebecca L Stone; Robert L Coleman; Ronald D Alvarez; Gabriel Lopez-Berestein; Anil K Sood; Charles N Landen
Journal:  Clin Cancer Res       Date:  2011-07-13       Impact factor: 12.531

8.  Chitosan-based hybrid nanocomplex for siRNA delivery and its application for cancer therapy.

Authors:  Min-Hyo Ki; Ji-Eon Kim; Young-Nam Lee; Sang Myoung Noh; Sung-Won An; Hyun-Jong Cho; Dae-Duk Kim
Journal:  Pharm Res       Date:  2014-05-24       Impact factor: 4.200

9.  Targeting cancer cell integrins using gold nanorods in photothermal therapy inhibits migration through affecting cytoskeletal proteins.

Authors:  Moustafa R K Ali; Yue Wu; Yan Tang; Haopeng Xiao; Kuangcai Chen; Tiegang Han; Ning Fang; Ronghu Wu; Mostafa A El-Sayed
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-26       Impact factor: 11.205

10.  Nanog signaling in cancer promotes stem-like phenotype and immune evasion.

Authors:  Kyung Hee Noh; Bo Wook Kim; Kwon-Ho Song; Hanbyoul Cho; Young-Ho Lee; Jin Hee Kim; Joon-Yong Chung; Jae-Hoon Kim; Stephen M Hewitt; Seung-Yong Seong; Chih-Ping Mao; T-C Wu; Tae Woo Kim
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.